Valentina Pirazzoli

author (P50)

Q33819404	Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.
Q36471537	Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma
Q37475038	De novo selection of oncogenes
Q39208997	Direct evidence of the importance of vitronectin and its interaction with the urokinase receptor in tumor growth
Q39964579	Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5.
Q51755079	Generation of drug-resistant tumors using intermittent dosing of tyrosine kinase inhibitors in mouse.
Q36322762	HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation
Q37138662	Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance
Q36622817	Noncovalent wild-type-sparing inhibitors of EGFR T790M
Q37095651	Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells
Q35112467	Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer

Reverse relations